Seborrheic Keratosis in the Auricle

: A Rare Tumor

Show less

Chang Eui Hong, MD, Yeejeong Kim, MD, PhD, Hyun Seung Choi, MD, 

Junhui Jeong, MD, PhD

First Published February 12, 2019 Research Article 

https://doi.org/10.1177/0145561319830069

Article information

 

Article Information

Article first published online: February 12, 2019

Chang Eui Hong, MD¹, Yeejeong Kim, MD, PhD², Hyun Seung Choi, MD¹,  Junhui Jeong, MD, PhD¹

¹Department of Otorhinolaryngology, National Health Insurance Service Ilsan Hospital, Goyang, Korea

²Department of Pathology, National Health Insurance Service Ilsan Hospital, Goyang, Korea

Corresponding Author: Junhui Jeong, MD, PhD, Department of Otorhinolaryngology, National Health Insurance Service Ilsan Hospital, 100 Ilsan-ro, Ilsandong-gu, Goyang 10444, Korea. Email: jeongj@nhimc.or.kr

Abstract

Seborrheic keratosis (SK) is a common, benign, cutaneous skin tumor of the elderly patients. It is commonly observed in the head, neck, trunk, and extremities except the palms and soles. Its occurrence in the auricle has been reported even more rarely than in external auditory canal. We experienced rare SK in the auricle that was completely removed and did not recur.

Keywords seborrheic keratosis, auricle, elderly, skin

A 65-year-old man visited our clinic complaining of a left auricular mass for the past 10 years, which recently began slowly growing. The patient reported that there was no pain or itching in the lesion. He had no known history of trauma or excessive exposure to ultraviolet light. He also had no familial history of this type of lesion and it was only in the auricle. The mass appeared as a brownish, papillomatous, verrucous lesion, about 2 cm × 2 cm, located at the cavum concha, cymba concha, and crus of the helix (Figure 1). Considering the possibility of malignancy, complete excisional biopsy was planned under local anesthesia.

Figure 1. A brownish, papillomatous, verrucous mass is shown at the cavum concha, cymba concha, and crus of the helix.

Intraoperative frozen pathology suggested it to be a benign lesion such as seborrheic keratosis (SK). After excluding the possibility of malignancy, the lesion was removed completely with the shave excision method. In permanent pathologic diagnosis, hyperkeratotic and acanthotic SK was reported. Histologically, the lesion showed acanthosis and papillomatosis with hyperkeratosis. The epidermis showed proliferation of basaloid and squamoid cells. Several pseudohorn cysts were present (Figure 2). After 1 month, the excised skin was well healed with application of antibiotic ointment. After 1 year, there was no recurrence or complication.

Figure 2. Histopathologic image shows hyperkeratosis, papillomatosis, and proliferation of basaloid cells (arrow) and pseudohorn cyst (arrowhead; hematoxylin–eosin, ×100).

Seborrheic keratosis is a common, benign, cutaneous skin tumor of the elderly patients.^1-3 It is commonly observed in the head, neck, trunk, and extremities except the palms and soles.^1-4 Its occurrence in the auricle has been reported even more rarely than in external auditory canal.

Seborrheic keratosis is also known as seborrheic verruca, seborrheic wart, verruca senilis, senile wart, basal cell acanthoma, benign keratoacanthoma, and basal cell papilloma.¹ It presents as solitary or multiple, round-to-oval, coin-like plaques of variable size and can present on many sites of the body.^1,5 It is rare and unusual in the external auditory canal^2,4 and even rarer in the auricle. To date, 6 cases of auricular SK have been reported in the English literature. It is more prevalent among Caucasians, and there is no prevalent difference between men and women. It is thought that SK increases with age.¹

The pathophysiology of SK has not yet been established, but ultraviolet exposure, human papillomavirus infection, and hormonal effects have been associated with it.² Seborrheic keratosis involves monoclonal tumors and autonomous neoplasms rather than simple epidermal hyperplastic disease. The fibroblast growth factor receptor 3 gene and p110 α subunit of phosphoinositide 3-kinase oncogene mutations are reported to be involved in the pathogenesis of SK.¹

There are several histologic microscopic subtypes of SK, which consist of acanthotic, hyperkeratotic, adenoid or reticulated, clonal, irritated, inverted follicular keratosis, and melanoacanthoma types.² Acanthotic, hyperkeratotic, and adenoid are the major subtypes, of which acanthotic is the most common.¹

There are several benign and malignant diseases that should be differentiated from SK, such as actinic keratosis, solar lentigo, fibroma, verruca vulgaris, keratoacanthoma, basal cell carcinoma, squamous cell carcinoma, and melanoma.^1,2 It is important to evaluate the possibility of malignancy when a lesion suspicious of SK is detected. It has been reported that basal or squamous cell carcinoma has coexisted with SK.³ However, SK in the external auditory canal and auricle has not been reported to be associated with concomitant malignancy.⁴

The treatment of choice for SK is removal using various methods including curettage, cryotherapy, laser ablation, topical vitamin D, and complete excision.¹ Although SK is benign, considering its potential local recurrence and concomitant malignant features, close follow-up is necessary.²

Seborrheic keratosis in the auricle is rarer than in the external auditory canal; however, due to its location, it is easier to detect it in the auricle than in the external auditory canal. When the lesion is suspicious of malignancy, complete removal should be performed. In all excised cases, pathologic confirmation is mandatory to evaluate malignancy.

Authors' Note
The institutional review board of National Health Insurance Service Ilsan Hospital exempted the review of this study (NHIMC 2018-07-003).

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Junhui Jeong, MD, PhD https://orcid.org/0000-0002-1592-261X

References

1.	Kim, KW, Chang, J, Lee, S. Clinical analysis of seborrheic keratoses in the ear: a retrospective study and literature review. Eur Arch Otorhinolaryngol. 2015;272(5):1113–1117.  Google Scholar | Crossref
2.	Kim, JH, Kim, H, Kang, JW. Dark brownish cutaneous mass in the cavum concha. JAMA Otolaryngol Head Neck Surg. 2014;140(6):571–572.  Google Scholar | Crossref
3.	Choi, JH . Seborrheic keratosis of the external auditory canal. Otol Neurotol. 2012;33(4):e27–e28.  Google Scholar | Crossref
4.	Izquierdo Velásquez, JC, Campos Mahecha, AM, Duarte Silva, JP. Seborrheic keratosis of the external auditory canal. Otol Neurotol. 2012;33(7):e61–e62.  Google Scholar | Crossref
5.	Magliulo, G, Ciniglio Appiani, M. Seborrheic keratosis, keratotic type, of the external auditory canal. Otolaryngol Head Neck Surg. 2011;145(4):697–698.  Google Scholar | SAGE Journals

View Abstract

Endoscopic Sphenopalatine Artery Ligation

: General Applicability in a Teaching Unit

Shi Ying Hey, MRCS, DO-HNS, Nigel K. F. Koo Ng, MA, FRCS (ORL-HNS), DO-HNS, Gerald W. McGarry, MD, FRCS (ORL-HNS), FRCSEd, FFSTEd

First Published February 12, 2019 Research Article 

https://doi.org/10.1177/0145561319828675

Article information

 

Article Information

Article first published online: February 12, 2019

 Shi Ying Hey, MRCS, DO-HNS¹, Nigel K. F. Koo Ng, MA, FRCS (ORL-HNS), DO-HNS¹, Gerald W. McGarry, MD, FRCS (ORL-HNS), FRCSEd, FFSTEd¹

¹Department of Otolaryngology–Head and Neck Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom

Corresponding Author: Shi Ying Hey, MRCS, DO-HNS, Department of Otolaryngology-Head and Neck Surgery, Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, 84 Castle Street, Glasgow G4 0SF, United Kingdom. Email: shiying.hey@nhs.net

Abstract

Background:

Endoscopic sphenopalatine artery ligation (ESPAL) is the intervention of choice for refractory epistaxis in specialist ear, nose and throat (ENT)units and should be within the repertoire of competencies for all ENT trainees. Following its recent incorporation within the United Kingdom competency–based training syllabus as an explicit outcome standard, the ESPAL is not uncommonly being delivered by trainees under appropriate supervision. We assessed the efficacy and outcome of ESPAL in epistaxis management within our teaching hospitals.

Methods:

Retrospective, structured review of all ESPAL procedures performed for epistaxis between December 2005 and December 2013. The techniques of ligation, operator grade, and outcome were studied.

Results:

Sixty-five patients (41 male:24 female; average age of 58.2 years) were identified in whom 67 artery ligations were performed (63 unilateral; 2 bilateral). Overall, success rate of ESPAL was 92.3% (60/65), with 5 rebleed cases recorded within 30 days of the primary procedure. Sixteen (24.6%) underwent "clipping," 26 (40.0%) had diathermy ligation, 18 (27.7%) had both clipping and diathermy, and in 5 (7.7%) patients, the ligation technique was not recorded. In 31 (47.7%) of 65 cases, a consultant was the principal surgeon. The remaining 34 (52.3%) of 65 cases were performed by trainees with (24, 70.6%) or without (10, 29.4%) supervision. There was no correlation between rebleed and operators' grade, level of supervision, or ligation technique.

Conclusion:

With appropriate training, ESPAL can achieve hemostasis in teams of varying grades of operators without significant reduction in outcome. To further enhance the technical learning curve, the utility of simulation-based training could offer continuous and longitudinal development of skills.

Keywords epistaxis, sphenopalatine artery ligation, endoscopy

Introduction

Epistaxis is the commonest emergency in ear, nose and throat (ENT), with an estimated incidence of 108 in 100 000 population per year.¹ In Scotland, this accounts for 1 in 3 of all ENT emergency admissions.²Effective initial management consists of localization of and direct therapy to the bleeding source (eg, silver nitrate cautery or bipolar diathermy) or application of localized pressure at the bleeding point with targeted, nasal packing. Despite being a common presentation, the management of epistaxis can be challenging due to its varying severity. The current lack of national guidelines results in management being dictated by the availability of local resources and personnel.^3,4 While the majority of cases are conservatively managed, intractable epistaxis results in significant morbidity and even mortality, avoidance of which necessitates early surgical intervention in the form of artery ligation or embolization. With increasing refinements in endoscopic techniques and anatomical understanding of the locoregional nasal vasculature, endoscopic sphenopalatine artery ligation (ESPAL) has gradually emerged as the surgical intervention of choice for refractory epistaxis in specialist ENT units. Due to it being the most distal blood supply to the nasal cavity, ligation of sphenopalatine artery has gained popularity over the conventional approaches of external carotid and maxillary artery ligation, providing an inherently effective and localized control of epistaxis achievable endonasally with minimal access and minimal morbidity. Current evidence which comprises mainly of cohort studies has demonstrated that ESPAL benefits from both clinical and cost-effectiveness superiority, indicated by a high success rate of up to 100% in expert hands as well as shorter hospital stay.^5–7

Not only in the expert hands, being the intervention of choice for intractable epistaxis, ESPAL should also be within the repertoire of competencies for all ENT surgeons. Following its recent incorporation within the United Kingdom competency-based training syllabus as an explicit outcome standard upon the completion of training to becoming an independent practitioner, the trainee must be able to demonstrate ability to perform ESPAL with minimum supervision. Due to the engendered training appetite, it is therefore not uncommon for the ESPAL being increasingly delivered by trainees under appropriate supervision, especially in teaching units. The aim of this study was to assess the efficacy and outcome of ESPAL in epistaxis management as it is used by all grades of operator within our teaching hospitals.

Methods

Study approval was obtained from NHS Greater Glasgow and Clyde clinical governance committee for surgery. A retrospective and structured review of records of ESPALs performed within all NHS North Glasgow hospitals over an 8-year period between December 2005 and December 2013 was conducted. All patients who underwent ESPAL were identified and indications for ESPAL were studied. Those patients in whom ESPAL was used for management of epistaxis were included in the study, while those who underwent ESPAL as an elective procedure in assisting the endoscopic excision of sinonasal tumors were excluded. Information on the techniques of ligation, operative details, and operator grade were extracted from operation notes. The efficacy of ESPAL and any related complications were specifically recorded.

Success measure for an ESPAL procedure was defined as no further epistaxis or rebleed within 30 days of the index procedure, whereas any presentation of epistaxis out with this period of time was classified as a late rebleed and was recalled but not included in the primary failure rate. Where appropriate, statistical analysis was performed using Fisher exact or χ² (GraphPad Prism, LaJolla, California).

Results

A total of 65 patients (41 male:24 female) underwent ESPAL for epistaxis management during the study period, in whom 67 artery ligations were performed (63 unilateral; 2 bilateral). The mean age of the study population was 58.2 years (range: 21-87 years). Overall, the follow-up period ranged from 1 to 8 years.

Efficacy

The overall success rate of ESPAL was 92.3% (60/65). Within 30 days of the primary procedure, a total of 5 (7.7%) rebleed cases were identified in which 2/5 had occurred within 24 hours and 3/5 were within 30 days. All 5 rebleed cases were recorded from the ipsilateral side of the initial presentation and among these, 4/5 had required readmission while 1/5 had occurred during the index admission. The outcome of the rebleed patients are summarized in Table 1.

Table 1. Outcome of Patients With Rebleed Following the ESPAL Procedure.a

Table 1. Outcome of Patients With Rebleed Following the ESPAL Procedure.^a

View larger version

Of these 5 patients who had an unsuccessful primary procedure, there was only 1 case in which repeat ESPAL was performed. This was at 2-week interval from the index procedure requiring a readmission. Intraoperative findings confirmed division of the inferior turbinate branch of the sphenopalatine artery but intact posterior septal branches. Further diathermy and division was therefore carried out on the residual branches of the sphenopalatine artery and there was no subsequent epistaxis.

Surgical Techniques

The technique used for sphenopalatine artery ligation was analyzed. Of all 65 patients, 16 (24.6%) underwent "clipping" of the artery, 26 (40.0%) underwent diathermy, 18 (27.7%) had both clipping and diathermy, and in 5 (7.7%) patients, the ligation technique was not recorded. Within the remit of available data, there was no demonstrable superiority of clip application or diathermy in securing the sphenopalatine artery (P = .1893).

Operator Grade

In 31 (47.7%) of 65 cases, a consultant was the principal operating surgeon. The remaining 34 (52.3%) of 65 cases were performed by trainees with (24, 70.6%) or without (10, 29.4%) supervision by a consultant. There was no specific correlation observed between rebleed and operators' grade (P = 1.0000).

Late Rebleed Patients

In addition, a further 5 patients were identified during the follow-up study period where ipsilateral epistaxis had occurred beyond 30 days of the index procedure. These were recorded within a wide range of period from 6 weeks to 18 months. Of these 5 patients, 2 patients had spontaneous resolution following admission, 1 patient had nasal packing, 1 patient underwent examination under general anesthesia where generalized mucosal ooze was identified and managed with both diathermy and Floseal^® (Baxter, Hayward, CA, US), while 1 patient had sphenopalatine foramen exploration which did not identify any remaining branches and an anterior ethmoidal ligation was subsequently performed.

Follow-Up

During the follow-up period, 4 patients died due to unrelated comorbidities at a period ranging between 6 and 38 months. In addition to rebleed cases, there were 2 postoperative complications recorded. One patient sustained an ipsilateral corneal abrasion due to the routine untaping of the eye and was reviewed postoperatively by ophthalmology. Topical antibiotics was commenced and there was no long-term sequelae. One patient developed dense postoperative adhesions requiring division both under local and general anesthesia; however, this was felt to be due to extensive and unsuccessful silver nitrate cautery prior to ESPAL.

Discussions

Endoscopic sphenopalatine artery ligation represents an effective and safe treatment of choice in refractory epistaxis, as evidenced by a 92.3% success rate from our series. Notably, this can be achieved by varying grades of operators without significant reduction in outcome. While the method of securing the sphenopalatine vessels remains a contentious issue, our series has shown no demonstrable superiority from either clips or diathermy application. With no current national consensus on epistaxis management or the optimal timing for surgical intervention, ESPAL is usually indicated in common practice after a watchful waiting period of up to 48 hours for persistent epistaxis.^8,9 The minimally invasive nature and high efficacy of ESPAL continue to support its preeminence in the management for refractory epistaxis and it should be considered as early definitive management of epistaxis not amenable to conservative measures. In practical terms, we therefore advocate for epistaxis not controlled within 12 hours of admission, that a senior member of the team (registrar grade or above) should be contacted with a view to consider an ESPAL procedure.

Our routine experience of ESPAL management of epistaxis has a success rate consistent with previously published cohort studies. This series of patients represents, to our knowledge, the largest group of epistaxis patients managed with ESPAL reported to date, also including multiple operators of varying grades.^10–12

Being the current treatment of choice for refractory epistaxis, it is increasingly been recognized, particularly within the United Kingdom competency-based training syllabus, that ESPAL should be within the repertoire of competencies for all ENT trainees. Nevertheless, similar to most emergency operations, the acquisition of proficiency and training opportunities for ESPAL can be rendered ad hoc, for not uncommonly performed out of hours thus infrequently encountered by trainees. Furthermore, the on-going shaping and configuring of surgical training in the United Kingdom, in conjunction with the European Working Time Directive implementation, has shifted the paradigm toward competence-based training, which can inadvertently reduce the overall training time and operative experience in the emergency settings.

In parallel to these, the engendered training appetite has resulted in ESPAL increasingly being delivered by trainees, under appropriate supervision and guidance. Although ESPAL remains a procedure performed for over 20 years with outcomes published in various cohort studies, our series is novel in studying and comparing the operative outcomes by varying grades of surgeons. Interestingly, our study did not show less efficacious outcome with ESPAL performed by trainees with appropriate supervision (70.6%) or in capable trainees when operating unsupervised (29.4%). The favorable outcome by trainees is likely to be underpinned by transferable competencies acquired from the robust training within the elective settings in a range of endoscopic skills, prior to its applications in the emergency procedure. To further enhance the technical learning curve for ESPAL, the utility of simulation training could offer continuous development of skills in a longitudinal manner.

Our study has also highlighted the importance of appreciating variation in the sphenopalatine artery, which should prompt the surgeon to always actively search for all branches, including those posterior to the sphenopalatine foramen.¹³ Of note, a small group of late rebleed patients during the follow-up period were identified which occurred beyond 30 days of index procedure. This is unlikely to be attributed to the commonly perceived technical failure of clip dislodgement or incomplete division of vessels, but rather raises the possibility of subsequent neovascularization. As there is no known similar study with a prolonged follow-up post-ESPAL, the true incidence of this phenomenon can be difficult to ascertain. It, nevertheless, poses an interesting observation for studies in nasal vascular anatomy.

Although embolization has been shown to have equal efficacy to ESPAL in cessation of refractory epistaxis, in our practice, this tends to be reserved in patients with anesthetic concern or rebleed cases. This is, in part, due to the limited availability of embolization which has its own significant risks. Furthermore, ESPAL has been shown to be superior to embolization in terms of cost-effectiveness.¹⁴ In the current climate of an aging population with increasing comorbidities, patients' suitability for general anesthesia can often become the main drawback for performing ESPAL. A recent study, however, has reported performing ESPAL under local anesthesia,¹⁵ thereby circumventing the anesthetic fitness barrier and thus potentially extend the applicability of the procedure.

Conclusions

With an overall success rate of 92.3%, it would be appropriate to consider ESPAL as an early definitive management for intractable epistaxis. Endoscopic sphenopalatine artery ligation requires a sound understanding of the anatomical variation of sphenopalatine artery to ensure technical success. With appropriate training, there is no difference in outcome between ESPAL procedures performed by trainees compared to consultants. Thus, protocols should be developed that mandate the implementation of ESPAL in uncontrolled epistaxis.

Authors' Note
Oral presentation at 25th Congress of the European Rhinologic Society, on June 22-26, 2014; Scottish Otolaryngological Society (ENT Scotland) Summer Meeting, on May 13, 2016.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Shi Ying Hey, MRCS, DO-HNS https://orcid.org/0000-0003-3845-2566

References

1.	O'Donnell, M, Robertson, G, McGarry, GW. A new bipolar diathermy probe for the outpatient management of adult acute epistaxis. Clin Otolaryngol Allied Sci. 1999;24(6):537–41.  Google Scholar | Crossref
2.	Walker, TW, Macfarlane, TV, McGarry, GW. The epidemiology and chronobiology of epistaxis: an investigation of Scottish hospital admissions 1995-2004. Clin Otolaryngol. 2007;32(5):361–365.  Google Scholar | Crossref
3.	Hall, AC, Blanchford, H, Chatrath, P, Hopkins, C. A multi-centre audit of epistaxis management in England: is there a case for a national review of practice? J Laryngol Otol. 2015;129(5):454–457.  Google Scholar | Crossref
4.	Melia, L, McGarry, GW. Epistaxis: update on management. Curr Opin Otolaryngol Head Neck Surg. 2011;19(1):30–35.  Google Scholar | Crossref
5.	Voegels, RL, Thomé, DC, Iturralde, PP, Butugan, O. Endoscopic ligature of the sphenopalatine artery for severe posterior epistaxis. Otolaryngol Head Neck Surg. 2001;124(4):464–467.  Google Scholar | SAGE Journals
6.	O'Flynn, PE, Shadaba, A. Management of posterior epistaxis by endoscopic clipping of the sphenopalatine artery. Clin Otolaryngol Allied Sci. 2000;25(5):374–377.  Google Scholar | Crossref
7.	Sharp, HR, Rowe-Jones, JM, Biring, GS, Mackay, IS. Endoscopic ligation or diathermy of the sphenopalatine artery in persistent epistaxis. J Laryngol Otol. 1997;111(11):1047–1050.  Google Scholar | Crossref
8.	Hall, AC, Simons, M, Pilgrim, G, Theokli, C, Roberts, D, Hopkins, C. Epistaxis management at Guy's Hospital, 2009-2011: full audit cycles. J Laryngol Otol. 2014;128(1):82–85.  Google Scholar | Crossref
9.	Daudia, A, Jaiswal, V, Jones, NS. Guidelines for the management of idiopathic epistaxis in adults: how we do it. Clin Otolaryngol. 2008;33(6):618–620.  Google Scholar | Crossref
10.	Abdelkader, M, Leong, SC, White, PS. Endoscopic control of the sphenopalatine artery for epistaxis: long-term results. J Laryngol Otol. 2007;121(8):759–762.  Google Scholar | Crossref
11.	George, A, Smatanova, K, Joshi, H, Jervis, S, Oluwole, M. Sphenopalatine, anterior ethmoid and internal maxillary artery intervention in the management of refractory epistaxis: their efficacy in 25 patients. Clin Otolaryngol. 2012;37(4):321–325.  Google Scholar | Crossref
12.	McDermott, AM, O'Cathain, E, Carey, BW, O'Sullivan, P, Sheahan, P. Sphenopalatine artery ligation for epistaxis: factors influencing outcome and impact of timing of surgery. Otolaryngol Head Neck Surg. 2016;154(3):547–552.  Google Scholar | SAGE Journals
13.	Loughran, S, Hilmi, O, McGarry, GW. Endoscopic sphenopalatine artery ligation—when, why and how to do it. An on-line video tutorial. Clin Otolaryngol. 2005;30(6):539–543.  Google Scholar | Crossref
14.	Rudmik, L, Leung, R. Cost-effectiveness analysis of endoscopic sphenopalatine artery ligation vs arterial embolization for intractable epistaxis. JAMA Otolaryngol Head Neck Surg. 2014;140(9):802–808.  Google Scholar | Crossref
15.	Yung, M, Sharma, R, Jablenska, L, Yung, T. A 2-cycle audit on the feasibility, efficacy and patient acceptance of 21 emergency sphenopalatine artery ligations under local anesthesia. Clin Otolaryngol. 2015. doi:10.1111/coa.12528. Epub 2016 Feb 8.  Google Scholar

View Abstract

The Full Moon on February 19th will be the biggest and brightest of 2019. .February’s full moon is commonly known as the Full Snow Moon. This year the Full Moon occurs on the Moon's closest point to Earth in it's orbit making it extra big and bright.

Neuro-Oncology Diet and risk of glioma

Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool Abstract Background Brain metastases are a common complication of renal cell carcinoma (RCC). Our group previously published the Renal Graded Prognostic Assessment (GPA) tool. In our prior RCC study (n = 286, 1985–2005), we found marked heterogeneity and variation in outcomes. In our recent update in a larger, more contemporary cohort, we identified additional significant prognostic factors. The purpose of this study is to update the original Renal-GPA based on the newly identified prognostic factors. Methods A multi-institutional retrospective institutional review board–approved database of 711 RCC patients with new brain metastases diagnosed from January 1, 2006 to December 31, 2015 was created. Clinical parameters and treatment were correlated with survival. A revised Renal GPA index was designed by weighting the most significant factors in proportion to their hazard ratios and assigning scores such that the patients with the best and worst prognoses would have a GPA of 4.0 and 0.0, respectively. Results The 4 most significant factors were Karnofsky performance status, number of brain metastases, extracranial metastases, and hemoglobin. The overall median survival was 12 months. Median survival for GPA groups 0–1.0, 1.5–2.0, 2.5–3, and 3.5–4.0 (% n = 25, 27, 30 and 17) was 4, 12, 17, and 35 months, respectively. Conclusion The updated Renal GPA is a user-friendly tool that will help clinicians and patients better understand prognosis, individualize clinical decision making and treatment selection, provide a means to compare retrospective literature, and provide more robust stratification of future clinical trials in this heterogeneous population. To simplify use of this tool in daily practice, a free online application is available at brainmetgpa.com. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients Abstract Background Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-ICLC in HLA-A2 + glioma patients. Methods Adult patients with newly diagnosed glioblastoma (n=16) and grade III astrocytoma (n=3) were treated with radiochemotherapy followed by IMA950/poly-ICLC vaccination. The first 6 patients received IMA950 (9 MHC class I and 2 MHC class II peptides) i.d. and poly-ICLC i.m. After protocol amendment, IMA950 and poly-ICLC were mixed and injected s.c. (n=7) or i.m. (n=6). Primary endpoints were safety and immunogenicity. Secondary endpoints were overall survival, progression-free survival at 6 and 9 months, and vaccine-specific peripheral CD4 and CD8 T cell responses. Results The IMA950/poly-ICLC vaccine was safe and well tolerated. Four patients presented cerebral edema with rapid recovery. For the first 6 patients, vaccine-induced CD8 T cell responses were restricted to a single peptide and CD4 responses were absent. After optimization of vaccine formulation, we observed multipeptide CD8 and sustained Th1 CD4 T cell responses. For the entire cohort, CD8 T cell responses to a single or multiple peptides were observed in 63.2% and 36.8% of patients, respectively. Median overall survival was 19 months for glioblastoma patients. Conclusion We provide, in a clinical trial, using cell surface-presented antigens, insights into optimization of vaccines generating effector T cells for glioma patients. Trial registration Clinicaltrials.gov NCT01920191. Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus Abstract The finding that most grade II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and CDKN2A/B deletional analysis. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Recent, ongoing and planned studies of radiation therapy and both cytotoxic and targeted chemotherapies are summarized, including both small molecule and immunotherapy approaches specifically targeting the mutant IDH protein. Diet and risk of glioma: combined analysis of three large prospective studies in the UK and USA Abstract Background Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimise possible differential dietary recall between those with and without glioma, we present findings from three large prospective studies. Methods Participants included 692,176 from (UK) Million Women Study, 470,780 from (US) NIH-AARP Study, and 99,148 from (US) PLCO Study. Cox regression yielded study-specific adjusted relative risks for glioma in relation to 15 food groups, 14 nutrients, and 3 dietary patterns, which were combined, weighted by inverse-variances of the relative risks. Separate analyses by <5 and ≥5 years follow-up assessed potential biases related to changes of diet before glioma diagnosis. Results The 1,262,104 participants, mean age 60.6 (SD5.5) at baseline, were followed for 15.4 million person-years (mean 12.2 years/participant), during which 2,313 incident gliomas occurred, at mean age 68.2 (SD6.4). Overall, there was weak evidence for increased glioma risks associated with increasing intakes of total fruit, citrus fruit, and fibre, and healthy dietary patterns, but these associations were generally null after excluding the first 5 years of follow-up. There was little evidence for heterogeneity of results by study or by sex. Conclusions The largest prospective evidence to date suggests little, if any, association between major food groups, nutrients, or common healthy dietary patterns, and glioma incidence. With the statistical power of this study and the comprehensive nature of the investigation here, it seems unlikely we have overlooked major effects of diet on risk of glioma that would be of public health concern.

Highlights from the Literature

Forthcoming Meetings Edited by Albert H. Kim and Jennie W. Taylor

Glioblastoma: a prognostic value of AMT-PET? See the article by John et al, pp. 264–273.

Old meet new—the path to combination treatments in pediatric low-grade gliomas See the article by Poore et al, pp. 252–263.

Disparities along the glioblastoma clinical trials landscape We read with interest the recent work by Vanderbeek et al1 regarding the current clinical trials landscape for glioblastoma (GBM) patients. An unexplored dimension of their analysis centers on disparities and demographic discrepancies between clinical trial participants and the broader GBM population. We therefore examined clinical trials with published results as highlighted by the authors, totaling 51 trials.1 While most of these trials reported details regarding patient age (48/51, 94%) and gender (47/51, 92%), only 14 trials (27%) provided information regarding ethnicity and/or race in either peer-reviewed publications or ClinicalTrials.gov. The rate of reporting ethnicity/race was particularly low among phase I/II studies (9/43, 21%) compared with phase III trials (5/8, 63%, chi-squared test P = 0.02).

Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival Abstract Background Although glioblastomas are heterogeneous brain-infiltrating tumors, their treatment is mostly focused on the contrast-enhancing tumor mass. In this study, we combined conventional MRI, diffusion-weighted imaging (DWI), and amino acid PET to explore imaging-defined glioblastoma subregions and evaluate their potential prognostic value. Methods Contrast-enhanced T1, T2/fluid attenuated inversion recovery (FLAIR) MR images, apparent diffusion coefficient (ADC) maps from DWI, and alpha-[11C]-methyl-L-tryptophan (AMT)-PET images were analyzed in 30 patients with newly diagnosed glioblastoma. Five tumor subregions were identified based on a combination of MRI contrast enhancement, T2/FLAIR signal abnormalities, and AMT uptake on PET. ADC and AMT uptake tumor/contralateral normal cortex (T/N) ratios in these tumor subregions were correlated, and their prognostic value was determined. Results A total of 115 MRI/PET-defined subregions were analyzed. Most tumors showed not only a high-AMT uptake (T/N ratio > 1.65, N = 27) but also a low-uptake subregion (N = 21) within the contrast-enhancing tumor mass. High AMT uptake extending beyond contrast enhancement was also common (N = 25) and was associated with low ADC (r = −0.40, P = 0.05). Higher AMT uptake in the contrast-enhancing tumor subregions was strongly prognostic for overall survival (hazard ratio: 7.83; 95% CI: 1.98–31.02, P = 0.003), independent of clinical and molecular genetic prognostic variables. Nonresected high-AMT uptake subregions predicted the sites of tumor progression on posttreatment PET performed in 10 patients. Conclusions Glioblastomas show heterogeneous amino acid uptake with high-uptake regions often extending into non-enhancing brain with high cellularity; nonresection of these predict the site of posttreatment progression. High tryptophan uptake values in MRI contrast-enhancing tumor subregions are a strong, independent imaging marker for longer overall survival.

Supratotal resection in glioma: a systematic review Abstract Background Emerging evidence suggests survival benefit from resection beyond all MRI abnormalities present on T1-enhanced and T2‒fluid attenuated inversion recovery (FLAIR) modalities in glioma (supratotal resection); however, the quality of evidence is unclear. We addressed this question via systematic review of the literature. Methods EMBASE, MEDLINE, Scopus, and Web of Science databases were queried. Case studies, reviews or editorials, non-English, abstract-only, brain metastases, and descriptive works were excluded. All others were included. Results Three hundred and nine unique references yielded 41 studies for full-text review, with 7 included in the final analysis. Studies were mostly of Oxford Center for Evidence-Based Medicine Level 4 quality. A total of 88 patients underwent supratotal resection in a combined cohort of 492 patients (214 males and 278 females, age 18 to 82 years). Fifty-one supratotal resections were conducted on high-grade gliomas, and 37 on low-grade gliomas. Karnofsky performance status, overall survival, progression-free survival, neurological deficits postoperatively, and anaplastic transformation were the main measured outcomes. No randomized controlled trials were identified. Preliminary low-quality support was found for supratotal resection in increasing overall survival and progression-free survival for both low-grade and high-grade glioma. Conclusion The literature suggests insufficient evidence for carte blanche application of supratotal resection, particularly in lower-grade gliomas where neurological deficits can result in long-term disability. While the preliminary studies discussed here, containing data from only a few centers, have reported increased progression-free and overall survival, these claims require validation in prospective research studies involving larger patient populations with clearly defined appropriate outcome metrics in order to reduce potential bias.

Uncommon low-grade brain tumors Abstract The 2016 World Health Organization (WHO) classification of primary central nervous system (CNS) tumors includes numerous uncommon (representing ≤1% of tumors) low-grade (grades I–II) brain neoplasms with varying clinical behaviors and outcomes. Generally, gross tumor or maximal safe resection is the primary treatment. Adjuvant treatments, though their exact role is unknown, may be considered individually based on pathological subtypes and a proper assessment of risks and benefits. Targetable mutations such as BRAF (proto-oncogene B-Raf), TRAIL (tumor necrosis factor apoptosis inducing ligand), and PDGFR (platelet derived growth factor receptor) have promising roles in future management.

Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose Abstract Background At our institution, we have historically treated brain metastasis (BM) ≤2 cm in eloquent brain with a radiosurgery (SRS) lower prescription dose (PD) to reduce the risk of radionecrosis (RN). We sought to evaluate the impact of this practice on outcomes. Methods We analyzed a prospective registry of BM patients treated with SRS between 2008 and 2017. Incidences of local failure (LF) and RN were determined and Cox regression was performed for univariate and multivariate analyses (MVAs). Results We evaluated 1533 BM ≤2 cm. Median radiographic follow-up post SRS was 12.7 months (1.4–100). Overall, the 2-year incidence of LF was lower for BM treated with PD ≥21 Gy (9.3%) compared with PD ≤15 Gy (19.5%) (sub–hazard ratio, 2.3; 95% CI: 1.4–3.7; P = 0.0006). The 2-year incidence of RN was not significantly higher for the group treated with PD ≥21 Gy (9.5%) compared with the PD ≤15 Gy group (7.5%) (P = 0.16). MVA demonstrated that PD (≤15 Gy) and tumor size (>1 cm) were significantly correlated (P < 0.05) with higher rates of LF and RN, respectively. For tumors ≤1 cm, when comparing PD ≤15 Gy with ≥21 Gy, the risks of LF and RN are equivalent. However, for lesions >1 cm, PD ≥21 Gy is associated with a lower incidence of LF without significantly increasing the risk of RN. Conclusion Our results indicate that rates of LF or RN following SRS for BM are strongly correlated with size and PD. Based on our results, we now, depending upon the clinical context, consider increasing PD to 21 Gy for BM in eloquent brain, excluding the brainstem.

Sex difference of mutation clonality in diffuse glioma evolution Abstract Background Sex differences in glioma incidence and outcome have been previously reported but remain poorly understood. Many sex differences that affect the cancer risk were thought to be associated with cancer evolution. Methods In this study, we used an integrated framework to infer the timing and clonal status of mutations in ~600 diffuse gliomas from The Cancer Genome Atlas (TCGA) including glioblastomas (GBMs) and low-grade gliomas (LGGs), and investigated the sex difference of mutation clonality. Results We observed higher overall and subclonal mutation burden in female patients with different grades of gliomas, which could be largely explained by the mutations of the X chromosome. Some well-established drivers were identified showing sex-biased clonality, such as CDH18 and ATRX. Focusing on glioma subtypes, we further found a higher subclonal mutation burden in females than males in the majority of glioma subtypes, and observed opposite clonal tendency of several drivers between male and female patients in a specific subtype. Moreover, analysis of clinically actionable genes revealed that mutations in genes of the mitogen-activated protein kinase (MAPK) signaling pathway were more likely to be clonal in female patients with GBM, whereas mutations in genes involved in the receptor tyrosine kinase signaling pathway were more likely to be clonal in male patients with LGG. Conclusions The patients with diffuse glioma showed sex-biased mutation clonality (eg, different subclonal mutation number and different clonal tendency of cancer genes), highlighting the need to consider sex as an important variable for improving glioma therapy and clinical care.